Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-025"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Variations to the terms of marketing authorisations for medicinal products - Counterfeiting of medicinal products (debate)2
dcterms:Language	"da"^^xsd:language2
lpv:document identification number	"en.20081022.2.3-025"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-0262
lpv:speaker	lp:Hanne Dahl2
lpv:spokenAs	unknown; JuniBevægelsen - Mod Unionen (2008-05-09--2009-07-13)3 member; AFCO (2008-05-09--2009-07-13)3 substitute; CONT (2008-05-09--2009-07-13)3 substitute; ENVI (2008-05-09--2009-07-13)3 substitute; IMCO (2008-05-09--2009-07-13)3 vice-chair; Delegation for relations with Switzerland, Iceland and Norway and to the European Economic Area (EEA) Joint Parliamentary Committee (2008-06-03--2009-07-13)3
lpv:translated text	"Mr President, I would like to take the liberty of giving a general, overall perspective since, up to now, EU harmonisation of medicinal product legislation has only involved relaxing the rules in Denmark. and the sale of medicines has increased. The new proposal with regard to marketing authorisations for medicines extends a helping hand to the pharmaceuticals industry. It will, in general, be easier to make small changes to medicines and release them under the same name, as mentioned by the previous speaker and, at the same time, it will be easier to change the name of a product if it is to be sold to treat a different pathology. There is a fear that these changes could make it more difficult for consumers to see the wood for the trees and make life easier for the pharmaceuticals industry. We also need to give consideration to the fact that the relationship between easier access to the authorisation of medicines and an increased risk for consumers is often, unfortunately, directly proportional. I am not saying that we should put unnecessary administrative obstacles in the way of the industry, but neither should we accept a slackening of the reins to make it easier for the pharmaceuticals industry to make a profit when it is people’s health and the health of animals that are at stake. In doing this, we will purely and simply be barking up the wrong tree. If we view it in a wider context, this directive is part of the industry’s efforts to improve profits in relation to the US. Let us not be naïve. We must not allow ourselves to be misled by fine-sounding, but empty statements relating to patients and consumers."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph